Corvus Pharmaceuticals, Inc. Stock

$4.14

2.59% yesterday

Nasdaq, Jul 11, 10:01 pm CET

ISIN

US2210151005

Symbol

CRVS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Corvus Pharmaceuticals, Inc. Stock price

$4.14

+0.21 5.34% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.11 2.59%

ISIN

US2210151005

Symbol

CRVS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$319.3m

Enterprise Value

$275.0m

Net debt

positive

Cash

$44.2m

Shares outstanding

68.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

6.5

Financial Health

Equity Ratio

47.3%

Return on Equity

-191.3%

ROCE

-62.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-31.1m | -

EBIT

$-31.2m | $-40.0m

Net Income

$-41.4m | $-23.1m

Free Cash Flow

$-28.6m

EPS

$-0.6

FCF per Share

$-0.4

Short interest

12.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Corvus Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

??

12 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:

11x Buy

92%

More details on Analyst Estimates Including Price Targets

12 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Corvus Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	8.45 8.45	19% 19% -
- Research and Development Expense	23 23	42% 42% -
EBITDA	-31 -31	36% 36% -
- Depreciation and Amortization	0.08 0.08	27% 27% -
EBIT (Operating Income) EBIT	-31 -31	35% 35% -
Net Profit	-41 -41	67% 67% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Corvus Pharmaceuticals, Inc. Stock News

Positive

24/7 Wall Street

●

about one month ago

3 Penny Stocks Wall Street Sees With 243% Upside

“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.

Neutral

GlobeNewsWire

●

about one month ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period ...

Neutral

GlobeNewsWire

●

about one month ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be...

More Corvus Pharmaceuticals, Inc. News

Company Profile

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.

Head office	United States
CEO	Richard Miller
Employees	31
Founded	2014
Website	www.corvuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now